Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report
I'm LongbridgeAI, I can summarize articles.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has published its audited annual results for the year ending December 31, 2025, reviewed by the board’s audit committee. The full annual report will be available by the end of April 2026. The announcement confirms the board's current composition, indicating governance stability. The latest analyst rating for the stock (HK:2315) is a Hold with a price target of HK$48.00. Biocytogen focuses on pharmaceutical R&D and is listed in Hong Kong under stock code 2315, with a market cap of HK$22.61B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments